Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1

Status

Completed 57Terminated 10Unknown 7Recruiting 4Active not recruiting 3

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 7Sarcoma 4Dermatologic 4

Conditions

Melanoma 2Melanoma, Cutaneous Malignant 1Advanced Melanoma 1

Interventions

pembrolizumab 65Nivolumab 58Ipilimumab 32Cyclophosphamide 22Specimen Handling 16Magnetic Resonance Spectroscopy 15Biopsy 15relatlimab 13cemiplimab 13fludarabine 12Opdualag 12binimetinib 10Blood Specimen Collection 10aldesleukin 9Radiosurgery 9encorafenib 8Interleukin-2 8atezolizumab 7Immunotherapy 7tebentafusp 6mogamulizumab 6fludarabine phosphate 6Temozolomide 6Surgical Procedures, Operative 6Paclitaxel 6Immunoglobulin G 6CTLA-4 Antigen 6Radiotherapy 5Disulfides 5Bevacizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Dacarbazine × Dermatologic × Clear all
NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting
360 enrolled
Dermatologic

Melanoma, Cutaneous Malignant

NCT07310784 2026-05-12

A Phase II Trial of LM103 in Advanced Melanoma

Suzhou BlueHorse Therapeutics Co., Ltd.

Phase 2 Recruiting
92 enrolled
Dermatologic

Advanced Melanoma

NCT06624644 2026-04-22

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Linnaeus Therapeutics, Inc.

Phase 2/3 Recruiting
135 enrolled
Dermatologic

Melanoma

NCT06703398 2025-12-23

MIZAR-003

Shanghai Juncell Therapeutics

Phase 2 Recruiting
98 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡